Lasa Historical Balance Sheet

LASA Stock

27.18 0.76 2.72%

Trend analysis of Lasa Supergenerics Limited balance sheet accounts such as Other Current Liab of 79 M provides information on Lasa Supergenerics' total assets, liabilities, and equity, which is the actual value of Lasa Supergenerics to its prevalent stockholders. By breaking down trends over time using Lasa Supergenerics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Lasa Supergenerics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lasa Supergenerics is a good buy for the upcoming year.

Lasa Supergenerics Inventory

195.3 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lasa Supergenerics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Lasa Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lasa Supergenerics at a specified time, usually calculated after every quarter, six months, or one year. Lasa Supergenerics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lasa Supergenerics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lasa currently owns. An asset can also be divided into two categories, current and non-current.

Lasa Supergenerics Balance Sheet Chart

At this time, Lasa Supergenerics' Non Currrent Assets Other are comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.7 B in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 209.7 M in 2024.

Common Stock Shares Outstanding Total Assets Short Long Term Debt Total Other Current Liab

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Lasa Supergenerics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lasa Supergenerics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most accounts from Lasa Supergenerics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lasa Supergenerics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lasa Supergenerics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	201.7M	217.7M	220.8M	209.7M
Total Assets	2.0B	1.6B	1.5B	1.7B

Short Long Term Debt Total Total Assets

Lasa Supergenerics balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab
Common Stock Shares Outstanding		-0.79	-0.93	0.91	-0.61	0.66	0.79	0.92	-0.81	-0.41	-0.94	-0.45	-0.56	0.42	-0.72	-0.19	-0.16	0.49	-0.9	0.71	0.34	-0.91	-0.9	0.51	-0.57	-0.95
Total Assets	-0.79		0.7	-0.8	0.84	-0.22	-0.81	-0.56	0.98	0.6	0.67	0.72	0.81	-0.14	0.97	-0.11	0.47	-0.23	0.87	-0.21	-0.08	0.61	0.81	-0.04	0.22	0.79
Short Long Term Debt Total	-0.93	0.7		-0.86	0.54	-0.83	-0.82	-0.95	0.69	0.33	0.99	0.37	0.44	-0.42	0.62	0.19	0.04	-0.47	0.93	-0.81	-0.27	0.99	0.92	-0.72	0.69	0.97
Other Current Liab	0.91	-0.8	-0.86		-0.46	0.48	0.73	0.84	-0.84	-0.58	-0.85	-0.65	-0.41	0.13	-0.68	-0.03	-0.1	0.25	-0.92	0.69	0.14	-0.85	-0.81	0.44	-0.65	-0.84
Total Current Liabilities	-0.61	0.84	0.54	-0.46		-0.22	-0.76	-0.38	0.77	0.4	0.55	0.29	0.97	-0.4	0.87	-0.15	0.62	-0.42	0.62	0.01	-0.22	0.41	0.75	0.05	-0.04	0.72
Total Stockholder Equity	0.66	-0.22	-0.83	0.48	-0.22		0.56	0.84	-0.2	0.02	-0.84	0.1	-0.11	0.54	-0.17	-0.35	0.19	0.53	-0.6	0.86	0.35	-0.86	-0.68	0.94	-0.68	-0.74
Other Liab	0.79	-0.81	-0.82	0.73	-0.76	0.56		0.75	-0.8	-0.39	-0.8	-0.45	-0.7	0.33	-0.81	0.3	-0.57	0.4	-0.83	0.48	0.27	-0.74	-0.84	0.38	-0.58	-0.86
Net Tangible Assets	0.92	-0.56	-0.95	0.84	-0.38	0.84	0.75		-0.58	-0.25	-0.96	-0.31	-0.32	0.36	-0.47	-0.23	0.01	0.41	-0.84	0.9	0.26	-0.97	-0.8	0.76	-0.77	-0.9
Property Plant And Equipment Net	-0.81	0.98	0.69	-0.84	0.77	-0.2	-0.8	-0.58		0.67	0.66	0.77	0.76	-0.1	0.95	-0.13	0.5	-0.22	0.86	-0.26	-0.12	0.62	0.78	-0.05	0.28	0.77
Current Deferred Revenue	-0.41	0.6	0.33	-0.58	0.4	0.02	-0.39	-0.25	0.67		0.3	0.56	0.46	0.26	0.49	-0.18	0.34	0.13	0.54	-0.15	0.06	0.31	0.41	-0.02	0.19	0.4
Net Debt	-0.94	0.67	0.99	-0.85	0.55	-0.84	-0.8	-0.96	0.66	0.3		0.28	0.45	-0.49	0.59	0.2	0.03	-0.54	0.89	-0.82	-0.33	0.98	0.93	-0.72	0.68	0.97
Retained Earnings	-0.45	0.72	0.37	-0.65	0.29	0.1	-0.45	-0.31	0.77	0.56	0.28		0.3	0.42	0.68	-0.12	0.26	0.29	0.65	-0.11	0.27	0.36	0.33	0.11	0.22	0.34
Accounts Payable	-0.56	0.81	0.44	-0.41	0.97	-0.11	-0.7	-0.32	0.76	0.46	0.45	0.3		-0.29	0.83	-0.16	0.7	-0.32	0.54	0.09	-0.17	0.31	0.64	0.16	-0.12	0.64
Cash	0.42	-0.14	-0.42	0.13	-0.4	0.54	0.33	0.36	-0.1	0.26	-0.49	0.42	-0.29		-0.23	-0.07	-0.11	0.98	-0.16	0.3	0.86	-0.37	-0.55	0.37	-0.18	-0.47
Non Current Assets Total	-0.72	0.97	0.62	-0.68	0.87	-0.17	-0.81	-0.47	0.95	0.49	0.59	0.68	0.83	-0.23		-0.18	0.6	-0.32	0.78	-0.1	-0.2	0.52	0.76	0.04	0.14	0.73
Non Currrent Assets Other	-0.19	-0.11	0.19	-0.03	-0.15	-0.35	0.3	-0.23	-0.13	-0.18	0.2	-0.12	-0.16	-0.07	-0.18		-0.69	-0.01	0.1	-0.28	0.16	0.26	0.05	-0.33	-0.19	0.15
Other Assets	-0.16	0.47	0.04	-0.1	0.62	0.19	-0.57	0.01	0.5	0.34	0.03	0.26	0.7	-0.11	0.6	-0.69		-0.18	0.15	0.3	-0.3	-0.07	0.21	0.38	-0.02	0.18
Cash And Short Term Investments	0.49	-0.23	-0.47	0.25	-0.42	0.53	0.4	0.41	-0.22	0.13	-0.54	0.29	-0.32	0.98	-0.32	-0.01	-0.18		-0.25	0.34	0.92	-0.43	-0.61	0.37	-0.26	-0.52
Net Receivables	-0.9	0.87	0.93	-0.92	0.62	-0.6	-0.83	-0.84	0.86	0.54	0.89	0.65	0.54	-0.16	0.78	0.1	0.15	-0.25		-0.63	-0.06	0.9	0.89	-0.5	0.57	0.92
Good Will	0.71	-0.21	-0.81	0.69	0.01	0.86	0.48	0.9	-0.26	-0.15	-0.82	-0.11	0.09	0.3	-0.1	-0.28	0.3	0.34	-0.63		0.27	-0.88	-0.59	0.91	-0.88	-0.68
Short Term Investments	0.34	-0.08	-0.27	0.14	-0.22	0.35	0.27	0.26	-0.12	0.06	-0.33	0.27	-0.17	0.86	-0.2	0.16	-0.3	0.92	-0.06	0.27		-0.25	-0.39	0.26	-0.29	-0.3
Non Current Liabilities Total	-0.91	0.61	0.99	-0.85	0.41	-0.86	-0.74	-0.97	0.62	0.31	0.98	0.36	0.31	-0.37	0.52	0.26	-0.07	-0.43	0.9	-0.88	-0.25		0.86	-0.8	0.74	0.92
Inventory	-0.9	0.81	0.92	-0.81	0.75	-0.68	-0.84	-0.8	0.78	0.41	0.93	0.33	0.64	-0.55	0.76	0.05	0.21	-0.61	0.89	-0.59	-0.39	0.86		-0.52	0.5	0.97
Other Current Assets	0.51	-0.04	-0.72	0.44	0.05	0.94	0.38	0.76	-0.05	-0.02	-0.72	0.11	0.16	0.37	0.04	-0.33	0.38	0.37	-0.5	0.91	0.26	-0.8	-0.52		-0.76	-0.58
Other Stockholder Equity	-0.57	0.22	0.69	-0.65	-0.04	-0.68	-0.58	-0.77	0.28	0.19	0.68	0.22	-0.12	-0.18	0.14	-0.19	-0.02	-0.26	0.57	-0.88	-0.29	0.74	0.5	-0.76		0.54
Total Liab	-0.95	0.79	0.97	-0.84	0.72	-0.74	-0.86	-0.9	0.77	0.4	0.97	0.34	0.64	-0.47	0.73	0.15	0.18	-0.52	0.92	-0.68	-0.3	0.92	0.97	-0.58	0.54

Click cells to compare fundamentals

Lasa Supergenerics Account Relationship Matchups

Lasa Supergenerics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	22.7M	22.9M	40.7M	50.1M	57.6M	39.2M
Total Assets	2.3B	2.1B	2.0B	1.6B	1.5B	1.7B
Short Long Term Debt Total	484.9M	194.6M	201.7M	217.7M	220.8M	209.7M
Other Current Liab	60.8M	63.4M	76.7M	114.2M	127.4M	79.0M
Total Current Liabilities	759.2M	405.4M	435.7M	427.3M	488.7M	531.6M
Total Stockholder Equity	1.4B	1.6B	1.5B	1.2B	966.8M	1.3B
Other Liab	3.6M	4.6M	84.1M	70.0M	80.5M	84.6M
Net Tangible Assets	990.2M	1.4B	1.5B	1.4B	1.7B	1.3B
Property Plant And Equipment Net	1.5B	1.4B	1.2B	927.8M	863.3M	1.1B
Current Deferred Revenue	75.8M	77.2M	73.3M	(217.7M)	226K	214.7K
Net Debt	459.3M	156.2M	91.3M	209.7M	214.7M	428.2M
Retained Earnings	32.8M	207.3M	144.1M	(253.7M)	(469.8M)	(446.3M)
Accounts Payable	337.3M	127.2M	169.1M	94.3M	140.5M	219.8M
Cash	25.7M	38.4M	110.4M	8.0M	6.1M	5.8M
Non Current Assets Total	1.6B	1.4B	1.3B	1.2B	1.1B	1.2B
Non Currrent Assets Other	(1.5B)	5.9M	(5K)	1K	7.1M	7.5M
Other Assets	39.3M	5.9M	(1K)	1K	900.0	855.0
Cash And Short Term Investments	25.7M	38.4M	171.9M	23.9M	15.0M	14.2M
Net Receivables	206.5M	147.7M	185.6M	24.8M	36.4M	34.6M
Liabilities And Stockholders Equity	2.3B	2.1B	2.0B	1.6B	1.5B	1.7B
Non Current Liabilities Total	146.0M	84.1M	70.0M	28.4M	53.2M	50.6M
Inventory	263.0M	172.6M	115.0M	139.0M	190.4M	195.3M
Other Current Assets	263.5M	279.0M	251.8M	229.3M	137.7M	242.3M
Total Liab	905.2M	489.4M	505.7M	455.7M	541.9M	764.1M
Short Long Term Debt	343.5M	194.6M	201.7M	217.7M	220.8M	244.4M
Total Current Assets	758.7M	643.2M	719.3M	392.2M	378.9M	564.0M
Accumulated Other Comprehensive Income	(501.7M)	(673.5M)	555.4M	515.8M	593.1M	622.8M
Cash And Equivalents	34.9M	5.6M	61.5M	15.9M	18.3M	21.8M
Short Term Debt	324.3M	174.5M	201.7M	217.7M	220.8M	214.8M
Intangible Assets	62.3M	54.5M	44.7M	185.3M	142.6M	93.0M
Property Plant Equipment	1.5B	1.4B	1.2B	927.8M	835.0M	1.1B
Net Invested Capital	1.9B	1.6B	1.5B	1.2B	1.2B	1.3B
Net Working Capital	(454K)	237.9M	283.6M	(35.1M)	(109.8M)	(104.3M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Lasa Stock Analysis

When running Lasa Supergenerics' price analysis, check to measure Lasa Supergenerics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lasa Supergenerics is operating at the current time. Most of Lasa Supergenerics' value examination focuses on studying past and present price action to predict the probability of Lasa Supergenerics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lasa Supergenerics' price. Additionally, you may evaluate how the addition of Lasa Supergenerics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC